Tackling The Workforce Crisis With A Scalable Solution: The Devereux ASCEND Case Study is starting in

FDA Issues Paper: Data & Methods For Evaluating The Impact Of Opioid Formulations With Properties Designed To Deter Abuse In The Postmarket Setting

On June 14, 2017, the Federal Food and Drug Administration (FDA) released this paper regarding data and methods for evaluating the impact of opioid formulations with properties designed to deter abuse in the postmarket setting. The paper is being presented prior to the July 10 and 11, 2017 public meeting . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.